New Share Alert | Okada Pharma Files for Hong Kong Listing

Stock News

01/27

It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors. According to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline. The company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1151443681"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151443681\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151443681?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151443681","market":"nz","top_or_hot":-1,"title":"New Share Alert | Okada Pharma Files for Hong Kong Listing","media":"Stock News","content":"<p>It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Share Alert | Okada Pharma Files for Hong Kong Listing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Share Alert | Okada Pharma Files for Hong Kong Listing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 08:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FT_SY_HEX","symbol_name":"港交所","start_time":0,"source_url":"","article_id":"1151443681","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151443681","pubTimestamp":1769472858,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK4020":"通信设备","AUDC":"奥科","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"新股快讯|冈田制药申请香港上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"HEXmain":1,"AUDC":1},"content_text":"It was disclosed by the Hong Kong Stock Exchange on January 26 that Shanghai Okada Pharmaceutical Technology Co., Ltd. (Okada Pharma) has submitted a listing application for the Main Board of the Hong Kong Stock Exchange, with CMBI and CCB International acting as its joint sponsors.\nAccording to the prospectus, Okada Pharma possesses its self-developed innovative drug delivery platform, has established an integrated internal system covering R&D, production, sales, and marketing, and has built a rich global product pipeline.\nThe company adopts the 505(b)(2) regulatory pathway, focusing on specific therapeutic areas, and leverages its self-constructed full-system capabilities in R&D, production, and commercialization to achieve operational synergies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}